[From AI to polygenic risk scores: which innovations will shape the future of psychiatry?]

Background: In recent years, developments have been made in various research domains, from treatments with (es)ketamine to large-scale genome-wide association studies (GWAS).

Aim: To map some of the most promising scientific developments, that may have an impact on clinical practice in psychiatry or are already doing so.

Method: We summarized recent developments in the field of epidemiology, artificial intelligence (AI) and genetics, supported by and illustrated with recent relevant scientific literature.

Results: Triangulation of data and innovative trial designs, such as n=1 trials and platform trials, carry the potential to contribute to more reliable results and developments in precision psychiatry. AI has various possibilities for daily practice: from searching for evidence to applying therapeutic interventions via chatbots. GWAS enable individual genetic risk profile generation with ever-growing precision.

Conclusion: Multifaceted developments in psychiatric research are projected to render clinical psychiatry more efficient and treatment options more personalized. Bolstering (international) collaborations and co-creating with experts by experience are indispensable elements in determining the scientific course in the field for the years ahead.